Stifel lowered the firm’s price target on DarioHealth (DRIO) to $1.25 from $1.50 and keeps a Buy rating on the shares. The firm’s projections assume the company has sufficient cash to fund operations through 2025 without accessing its credit line, but the firm contends the stock is unlikely to regain momentum until there are visible signs of accelerating revenue growth and a path to profitability, the analyst tells investors in a post-earnings note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRIO:
- DarioHealth Reports Increased Losses Amid Revenue Decline
- DarioHealth’s Revised Breakeven Timeline and Growth Prospects Amidst Current Challenges
- DarioHealth reports Q2 EPS 18c, consensus (10c)
- DarioHealth (DRIO) Q2 Earnings Cheat Sheet
- DarioHealth files to sell 8.77M shares of common stock for holders